Immune Design Presents New Preclinical Data on Advances of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immune Design Presents New Preclinical Data on Advances of Two Separate Intratumoral Approaches at the American Association for Cancer Research (AACR) Annual Meeting 2016
  • Curative Efficacy and Anti-tumor Immunity Demonstrated with Intratumoral Administration of IL-12 by a ZVex TM Vector
  • Systemic Anti-tumor Immunity Demonstrated with Intratumoral G100

SEATTLE and SOUTH SAN FRANCISCO, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ ), a clinical-stage immunotherapy company focused on oncology, today announced the presentation of new preclinical data demonstrating broad anti-tumor activity of its ZVex TM platform and further evidence of the anti-tumor activity of G100, both via intratumoral administration. Results were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans.

“These AACR data highlight the multi-faceted approaches that Immune Design is employing to generate a therapeutic anti-tumor immune response,” said Jan ter Meulen, MD, PhD, Chief Scientific Officer at Immune Design. “The results presented support for the first time the potential intratumoral applicability of Immune Design’s dendritic-cell targeting platform, ZVex, beyond its current use to generate an antigen-specific immune response via systemic administration. Moreover, we presented additional data supporting the ongoing clinical development of G100 as a novel approach to intratumoral immunization.”

Immune Design presented data describing the intratumoral administration of a ZVex Interleukin-12 (IL-12) vector to generate localized, intratumoral expression of IL-12. IL-12 is one of the most potent modulators of innate and adaptive immune response, but its use in the clinical setting has been limited due to toxicity when administered systemically. Results presented demonstrate strong local and systemic anti-tumor efficacy of the ZVex/IL-12 across multiple pre-clinical tumor models, including synergy when co-administrated with anti-CTLA-4 and GLA, Immune Design’s synthetic TLR4 agonist, Glucopyranosyl Lipid A, the core of Immune Design’s GLAAS TM platform. The AACR presentation was titled “Intratumoral expression of IL-12 from a dendritic cell-targeting chimeric lentiviral vector from the ZVex platform cures established tumors in multiple models and induces systemic anti-tumor responses” ( Abstract #4884 ).

In addition, Immune Design presented data highlighting the ability of its G100 product candidate, comprised of GLA in a stable emulsion, to modulate the tumor microenvironment and trigger local and systemic immune responses following its direct injection in a murine lymphoma model. G100 induced broad pro-inflammatory cytokine and chemokine responses, while also upregulating activating genes in immune cells, leading to the switch from a “cold” to a “hot” tumor state. In addition, the upregulation of checkpoints such as PD-L1 in the G100-treated tumors suggests potential synergy with immune checkpoint inhibitors. These data support IMDZ's ongoing trial of G100 in follicular non-Hodgkin lymphoma in combination with local radiation therapy and KEYTRUDA ®  (pembrolizumab), further described below. The AACR presentation was titled “Intratumoral Injection of G100 (TLR4 agonist Glycopyranosyl lipid A) modulates tumor microenvironment and induces CD8 T cell-dependent, systemic anti-tumor immunity” ( Abstract #4885 ).

About ZVex

ZVex is Immune Design's discovery platform designed to activate and expand the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs)  in vivo . The ZVex delivery system uses a re-engineered virus to carry genetic information of a tumor antigen selectively to dendritic cells (DCs) in the skin or lymph nodes. This ultimately results in the creation of CTLs designed to kill tumor cells bearing that same specific tumor antigen. ZVex is also designed to carry the genetic information for, and therefore potentially cause dendritic cells to express, multiple antigens and/or selected epitopes of interest (including neoantigens), as well as cytokines or other immunomodulatory molecules.

About G100

G100 is a product candidate generated from the company's GLAAS TM  discovery platform, and includes a specific formulation of Glucopyranosyl Lipid A (GLA), a synthetic, toll-like receptor-4 (TLR-4) agonist. G100 is part of Immune Design's intratumoral immune activation, or 'Endogenous Antigen,' approach to treating cancer, which leverages the activation of dendritic and other immune cells in the tumor microenvironment to potentially create a robust immune response against the tumor's preexisting diverse set of antigens. Preclinical and clinical data have demonstrated the ability of G100 to activate dendritic cells in tumors and to increase antigen-dependent systemic humoral and cellular Th1 immune responses. A Phase 1 study of G100 in patients with Merkel cell carcinoma (MCC) completed enrollment and preliminary data presented on the first eight patients demonstrated that G100 had an acceptable safety profile and resulted in an objective response rate (ORR) of 50% per protocol. The data presented today represent the potential expansion of the intratumoral immune activation approach to include the ZVex platform, as well.

G100 Study in Patients with Follicular Non-Hodgkin's Lymphoma

A Phase 1b/2 study evaluating intratumoral G100 in patients with follicular non-Hodgkin's lymphoma is currently enrolling patients ( NCT: 02501473 ). The study is evaluating the intratumoral administration of G100 with intravenous administration of KEYTRUDA ®  (pembrolizumab), Merck's anti-PD-1 therapy, in patients with follicular non-Hodgkin's lymphoma receiving local radiation, pursuant to a collaboration with Merck. The study is designed to evaluate G100 plus local radiation and KEYTRUDA ® compared to G100 plus local radiation alone. In addition to an evaluation of the safety of the combination, the study will assess the response in both injected and non-injected lesions.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight chronic diseases. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases.  CMB305 and G100, the primary focus of Immune Design's ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex and GLAAS, the fundamental technologies of which were licensed from the California Institute of Technology and the Infectious Disease Research Institute (IDRI), respectively.  Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com .

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Immune Design's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing of initiation, progress, scope and outcome of clinical trials for Immune Design's product candidates and the reporting of clinical data regarding Immune Design’s product candidates . Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Immune Design's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Other factors that may cause Immune Design's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Immune Design's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Immune Design assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Media Contact Julie Rathbun Rathbun Communications julie@rathbuncomm.com 206-769-9219 Investor Contact Shari Annes Annes Associates sannes@annesassociates.com 650-888-0902

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 59

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 161

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 266

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 238

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 18

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 286

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Beyond Meat Partners with Hard Rock Cafe for Burger Launch

Updated Category News Views 432

Beyond Meat and Hard Rock Cafe Collaboration Beyond Meat, Inc. (NASDAQ: BYND), an innovator in plant-based proteins, is excited to announce a partnership with Hard Rock Cafe, introducing the newest Beyond Burger across all its North American locations. This initiative allows diners to swap any beef burger from Hard Rock's core and kids' menus for the delicious and...

Continue Reading
ATEC Water Systems Welcomes Industry Leader Steve Green

Updated Category News Views 299

ATEC Water Systems welcomed Steve Green as their new Chief Commercial Officer back in 2024, shaking things up under the Cadiz, Inc. (NASDAQ: CDZI) umbrella. Traders watched closely; this wasn't just a run-of-the-mill hire but rather a strategic move aimed at revitalizing the company's trajectory in a crowded market. With Steve's extensive background in the water industry,...

Continue Reading
Mission Critical Group Welcomes Mark Feasel as VP of Sales

Updated Category News Views 249

Mission Critical Group Appoints New Vice President of Sales Mission Critical Group (MCG), a leader in critical power infrastructure solutions, is excited to announce the appointment of industry veteran Mark Feasel as the Vice President of Sales in the Commercial and Innovation Division. With this strategic addition, MCG aims to enhance its sales strategy and broaden its...

Continue Reading
Ascot Resources Explores Alternative TSXV Listing Options

Updated Category News Views 165

Ascot Resources Faces Delisting from TSX Ascot Resources Ltd., a Canadian mining company headquartered in Vancouver, is going through significant changes regarding its stock listings. Recently, the Continued Listing Committee of the Toronto Stock Exchange (TSX) informed Ascot that its common shares are set to be delisted at the market's close on a specified date. This...

Continue Reading
Albany International Corporation Faces Legal Scrutiny Amid Stockholder Concerns

Updated Category News Views 194

Introduction to the Investigation Albany International Corporation is currently experiencing legal scrutiny as concerns arise among stockholders regarding the company's financial performance. Recently, the law firm Bragar Eagel & Squire, P.C. has stepped in, urging investors who may have suffered losses in Albanian stocks to reach out for assistance. The firm seeks to...

Continue Reading